telmisartan trial summary

Heart failure

All type of patients: 1 trials - REPLACE

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Sudden death	no data
Death from any cause or hospitalization for any reason	no data
Cardiovascular death or hospital admission for CHF	no data
death or cardiovascular hospitalization	no data
Cardiovascular death	no data
hospitalisation for heart failure	no data
Hospitalization for any reason	no data
	no data
Hyperkalaemia	no data
Cough	0.58 [0.17 1.92]	p=1.00	0	378	1	REPLACE,
Hypotension	no data
angiodema	no data
Adverse events	1.79 [0.09 35.04]	p=1.00	0	378	1	REPLACE,
All cause death	0.51 [0.09 2.85]	p=1.00	0	378	1	REPLACE,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

See more clinical conditions

Patients already receiving ACE inhibitor: 1 trials - REPLACE

telmisartan vs enalapril

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Sudden death	no data
Death from any cause or hospitalization for any reason	no data
Cardiovascular death or hospital admission for CHF	no data
death or cardiovascular hospitalization	no data
Cardiovascular death	no data
hospitalisation for heart failure	no data
Hospitalization for any reason	no data
	no data
Hyperkalaemia	no data
Cough	0.58 [0.17 1.92]	p=1.00	0	378	1	REPLACE,
Hypotension	no data
angiodema	no data
Adverse events	1.79 [0.09 35.04]	p=1.00	0	378	1	REPLACE,
All cause death	0.51 [0.09 2.85]	p=1.00	0	378	1	REPLACE,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Hypertension

All diseases requiring ACEi (HF, CHD, HT,...): 3 trials - ONTARGET/Tel - DETAIL - PROPHESS

Telmisartan vs Enalapril

No demonstrated result

Endpoint	TE [95% CI]	p val	n	k	trials
Cardiovascular death	1.63 [0.27 9.90]	p=1.00	250	1	DETAIL,
myocardial infarction (fatal and non fatal)	1.63 [0.56 4.71]	p=1.00	250	1	DETAIL,
stroke (fatal and non fatal)	1.08 [0.34 3.46]	p=1.00	250	1	DETAIL,
All cause death	1.08 [0.34 3.46]	p=1.00	250	1	DETAIL,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

telmisartan vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.94 [0.87 1.02]	p=1.00	0	20332	1	PROPHESS,
Cardiovascular death	0.85 [0.71 1.02]	p=1.00	0	20332	1	PROPHESS,
myocardial infarction (fatal and non fatal)	1.00 [0.80 1.24]	p=1.00	0	20332	1	PROPHESS,
stroke (fatal and non fatal)	0.95 [0.86 1.04]	p=1.00	0	20332	1	PROPHESS,
Coronary event	no data
cardiac death	no data
cancer related death	no data
Heart failure	no data
All cause death	1.02 [0.92 1.14]	p=1.00	0	20332	1	PROPHESS,
lung cancer	1.24 [0.76 2.00]	p=1.00	0	20064	1	PROPHESS,
breast cancer	no data
prostate cancer	no data
Cancer	0.96 [0.82 1.12]	p=1.00	0	20064	1	PROPHESS,
Diabetes onset	0.83 [0.65 1.06]	p=1.00	0	20332	1	PROPHESS,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Telmisartan vs Ramipril

No demonstrated result

Endpoint	TE [95% CI]	p val	n	k	trials
Cardiovascular death	1.00 [0.89 1.12]	p=1.00	17118	1	ONTARGET/Tel,
myocardial infarction (fatal and non fatal)	1.07 [0.93 1.23]	p=1.00	17118	1	ONTARGET/Tel,
stroke (fatal and non fatal)	0.91 [0.79 1.06]	p=1.00	17118	1	ONTARGET/Tel,
All cause death	0.98 [0.89 1.07]	p=1.00	17118	1	ONTARGET/Tel,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

See more clinical conditions

All type of patient: 1 trials - PROPHESS

telmisartan vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.94 [0.87 1.02]	p=1.00	0	20332	1	PROPHESS,
Cardiovascular death	0.85 [0.71 1.02]	p=1.00	0	20332	1	PROPHESS,
myocardial infarction (fatal and non fatal)	1.00 [0.80 1.24]	p=1.00	0	20332	1	PROPHESS,
stroke (fatal and non fatal)	0.95 [0.86 1.04]	p=1.00	0	20332	1	PROPHESS,
Coronary event	no data
cardiac death	no data
cancer related death	no data
Heart failure	no data
All cause death	1.02 [0.92 1.14]	p=1.00	0	20332	1	PROPHESS,
lung cancer	1.24 [0.76 2.00]	p=1.00	0	20064	1	PROPHESS,
breast cancer	no data
prostate cancer	no data
Cancer	0.96 [0.82 1.12]	p=1.00	0	20064	1	PROPHESS,
Diabetes onset	0.83 [0.65 1.06]	p=1.00	0	20332	1	PROPHESS,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients undergoing dialysis : 1 trials - Cice et al

telmisartan vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	n	k	trials
cardiovascular events	0.79 [0.50 1.25]	p=1.00	303	1	Cice et al,
Cardiovascular death	0.79 [0.50 1.25]	p=1.00	303	1	Cice et al,
All cause death	0.71 [0.32 1.55]	p=1.00	114	1	Cice et al,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Post stroke: 1 trials - PROPHESS

telmisartan vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.94 [0.87 1.02]	p=1.00	0	20332	1	PROPHESS,
Cardiovascular death	0.85 [0.71 1.02]	p=1.00	0	20332	1	PROPHESS,
myocardial infarction (fatal and non fatal)	1.00 [0.80 1.24]	p=1.00	0	20332	1	PROPHESS,
stroke (fatal and non fatal)	0.95 [0.86 1.04]	p=1.00	0	20332	1	PROPHESS,
Coronary event	no data
cardiac death	no data
cancer related death	no data
Heart failure	no data
All cause death	1.02 [0.92 1.14]	p=1.00	0	20332	1	PROPHESS,
lung cancer	1.24 [0.76 2.00]	p=1.00	0	20064	1	PROPHESS,
breast cancer	no data
prostate cancer	no data
Cancer	0.96 [0.82 1.12]	p=1.00	0	20064	1	PROPHESS,
Diabetes onset	0.83 [0.65 1.06]	p=1.00	0	20332	1	PROPHESS,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Miscellaneous

All type of patients: 3 trials - ONTARGET (telmisartan alone) - TRANSCEND - PROPHESS

telmisartan vs placebo

No demonstrated result

suggested cardiovascular events by 8% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.92 [0.86 0.99]	p=0.04	0	26258	2	TRANSCEND,PROPHESS,
Cardiovascular death	0.93 [0.81 1.06]	p=1.00	0	26258	2	TRANSCEND,PROPHESS,
myocardial infarction (fatal and non fatal)	1.00 [0.80 1.24]	p=1.00	0	20332	1	PROPHESS,
stroke (fatal and non fatal)	0.93 [0.85 1.02]	p=1.00	0	26258	2	TRANSCEND,PROPHESS,
Coronary event	0.79 [0.62 1.02]	p=1.00	0	5926	1	TRANSCEND,
Coronary death	no data
cardiac death	no data
cardiovascular death, MI, stroke	0.88 [0.76 1.02]	p=1.00	0	5926	1	TRANSCEND,
cancer related death	no data
Non fatal MI	no data
Heart failure	no data
Revascularization	0.90 [0.77 1.05]	p=1.00	0	5926	1	TRANSCEND,
All cause death	1.03 [0.95 1.13]	p=1.00	0	26258	2	TRANSCEND,PROPHESS,
lung cancer	1.24 [0.76 2.00]	p=1.00	0	20064	1	PROPHESS,
breast cancer	no data
prostate cancer	no data
Cancer	0.96 [0.82 1.12]	p=1.00	0	20064	1	PROPHESS,
Cough	0.84 [0.42 1.67]	p=1.00	0	5926	1	TRANSCEND,
Hypotension	1.82 [0.99 3.36]	p=1.00	0	5926	1	TRANSCEND,
angiodema	0.67 [0.11 4.02]	p=1.00	0	5926	1	TRANSCEND,
Adverse events leading to treatment discontinuation	0.91 [0.81 1.03]	p=1.00	0	5926	1	TRANSCEND,
Diabetes onset	0.83 [0.65 1.06]	p=1.00	0	20332	1	PROPHESS,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

telmisartan vs ramipril

No demonstrated result

Hypotension by 54% (harmful effect)

suggested Cough by 74% (not demonstrated)

suggested angiodema by 60% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.99 [0.91 1.08]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
Cardiovascular death	1.00 [0.89 1.12]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
stroke (fatal and non fatal)	0.91 [0.79 1.06]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
Coronary event	1.07 [0.93 1.23]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
Coronary death	no data
cardiovascular death, MI, stroke	no data
Non fatal MI	no data
Revascularization	1.02 [0.94 1.11]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
All cause death	0.98 [0.89 1.07]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
Cough	0.26 [0.21 0.33]	p=0.04	0	17118	1	ONTARGET (telmisartan alone),
Hypotension	1.54 [1.25 1.90]	p=0.04	0	17118	1	ONTARGET (telmisartan alone),
angiodema	0.40 [0.19 0.84]	p=0.04	0	17118	1	ONTARGET (telmisartan alone),
Adverse events leading to treatment discontinuation	0.94 [0.87 1.01]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients at high risk for cardiovascular events

All type of patients: 3 trials - ONTARGET (telmisartan alone) - TRANSCEND - PROPHESS

telmisartan vs placebo

No demonstrated result

suggested cardiovascular events by 8% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.92 [0.86 0.99]	p=0.04	0	26258	2	TRANSCEND,PROPHESS,
Cardiovascular death	0.93 [0.81 1.06]	p=1.00	0	26258	2	TRANSCEND,PROPHESS,
myocardial infarction (fatal and non fatal)	1.00 [0.80 1.24]	p=1.00	0	20332	1	PROPHESS,
stroke (fatal and non fatal)	0.93 [0.85 1.02]	p=1.00	0	26258	2	TRANSCEND,PROPHESS,
Coronary event	0.79 [0.62 1.02]	p=1.00	0	5926	1	TRANSCEND,
Coronary death	no data
cardiac death	no data
cardiovascular death, MI, stroke	0.88 [0.76 1.02]	p=1.00	0	5926	1	TRANSCEND,
cancer related death	no data
Non fatal MI	no data
Heart failure	no data
Revascularization	0.90 [0.77 1.05]	p=1.00	0	5926	1	TRANSCEND,
All cause death	1.03 [0.95 1.13]	p=1.00	0	26258	2	TRANSCEND,PROPHESS,
lung cancer	1.24 [0.76 2.00]	p=1.00	0	20064	1	PROPHESS,
breast cancer	no data
prostate cancer	no data
Cancer	0.96 [0.82 1.12]	p=1.00	0	20064	1	PROPHESS,
Cough	0.84 [0.42 1.67]	p=1.00	0	5926	1	TRANSCEND,
Hypotension	1.82 [0.99 3.36]	p=1.00	0	5926	1	TRANSCEND,
angiodema	0.67 [0.11 4.02]	p=1.00	0	5926	1	TRANSCEND,
Adverse events leading to treatment discontinuation	0.91 [0.81 1.03]	p=1.00	0	5926	1	TRANSCEND,
Diabetes onset	0.83 [0.65 1.06]	p=1.00	0	20332	1	PROPHESS,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

telmisartan vs ramipril

No demonstrated result

Hypotension by 54% (harmful effect)

suggested Cough by 74% (not demonstrated)

suggested angiodema by 60% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.99 [0.91 1.08]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
Cardiovascular death	1.00 [0.89 1.12]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
stroke (fatal and non fatal)	0.91 [0.79 1.06]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
Coronary event	1.07 [0.93 1.23]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
Coronary death	no data
cardiovascular death, MI, stroke	no data
Non fatal MI	no data
Revascularization	1.02 [0.94 1.11]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
All cause death	0.98 [0.89 1.07]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
Cough	0.26 [0.21 0.33]	p=0.04	0	17118	1	ONTARGET (telmisartan alone),
Hypotension	1.54 [1.25 1.90]	p=0.04	0	17118	1	ONTARGET (telmisartan alone),
angiodema	0.40 [0.19 0.84]	p=0.04	0	17118	1	ONTARGET (telmisartan alone),
Adverse events leading to treatment discontinuation	0.94 [0.87 1.01]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

See more clinical conditions

Patients intolerant to ACE inhibitors: 1 trials - TRANSCEND

telmisartan vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.88 [0.76 1.02]	p=1.00	0	5926	1	TRANSCEND,
Cardiovascular death	1.02 [0.85 1.24]	p=1.00	0	5926	1	TRANSCEND,
stroke (fatal and non fatal)	0.83 [0.64 1.07]	p=1.00	0	5926	1	TRANSCEND,
Coronary event	0.79 [0.62 1.02]	p=1.00	0	5926	1	TRANSCEND,
Coronary death	no data
cardiovascular death, MI, stroke	0.88 [0.76 1.02]	p=1.00	0	5926	1	TRANSCEND,
Non fatal MI	no data
Revascularization	0.90 [0.77 1.05]	p=1.00	0	5926	1	TRANSCEND,
All cause death	1.05 [0.90 1.23]	p=1.00	0	5926	1	TRANSCEND,
Cough	0.84 [0.42 1.67]	p=1.00	0	5926	1	TRANSCEND,
Hypotension	1.82 [0.99 3.36]	p=1.00	0	5926	1	TRANSCEND,
angiodema	0.67 [0.11 4.02]	p=1.00	0	5926	1	TRANSCEND,
Adverse events leading to treatment discontinuation	0.91 [0.81 1.03]	p=1.00	0	5926	1	TRANSCEND,